User profiles for Pratish Patel

Pratish C Patel

- Verified email at vumc.org - Cited by 232

Pratish Patel

- Verified email at calpoly.edu - Cited by 88

The emperor's new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized …

…, MJ Zervos, CB Creech, PC Patel… - Clinical Infectious …, 2020 - academic.oup.com
Background Vancomycin is the most commonly administered antibiotic in hospitalized
patients, but optimal exposure targets remain controversial. To clarify the therapeutic exposure …

From natural disaster to pandemic: A health-system pharmacy rises to the challenge

AD Zuckerman, PC Patel, M Sullivan… - American Journal of …, 2020 - academic.oup.com
Purpose This report describes a health-system pharmacy’s response to a natural disaster
while staff members simultaneously prepared for the coronavirus disease 2019 (COVID-19) …

Unlocking Applications of Cell-Free Biotechnology through Enhanced Shelf Life and Productivity of E. coli Extracts

…, WY Kao, LC Williams, CM Hight, P Patel… - ACS Synthetic …, 2020 - ACS Publications
Cell-free protein synthesis (CFPS) is a platform biotechnology that enables a breadth of
applications. However, field applications remain limited due to the poor shelf-stability of aqueous …

COVID-19 treatments: then and now

SS Mustafa, RA Stern, PC Patel, DK Chu - The Journal of Allergy and …, 2023 - Elsevier
The coronavirus disease 2019 (COVID-19) pandemic has evolved over the past 3+ years,
and strategies to prevent illness and treat infection have changed over time. As COVID-19 …

Therapeutic drug monitoring of piperacillin and tazobactam by RP-HPLC of residual blood specimens

…, WH Fissell, A Seegmiller, J Colby, P Patel… - Clinica chimica acta, 2018 - Elsevier
Background Sepsis is a common diagnosis in critical care with inpatient mortality rates up to
50%. Sepsis care is organized around source control, antibiotics, and supportive care. Drug …

Lenacapavir (Sunlenca®) for the treatment of HIV-1

PC Patel, HK Beasley, A Hinton, CN Wanjalla - Trends in Pharmacological …, 2023 - cell.com
STRUCTURE: Lenacapavir (previously GS-6207, brand name Sunlenca®) is a small
molecule that selectively targets the HIV-1 capsid protein (CA, p24), which is a structural …

External Validation and Comparison of Clostridioides difficile Severity Scoring Systems

DA Perry, D Shirley, D Micic, PC Patel… - Clinical Infectious …, 2022 - academic.oup.com
Background Many models have been developed to predict severe outcomes from Clostridioides
difficile infection (CDI). These models are usually developed at a single institution and …

Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients

…, N Jimenez-Truque, W Fissell, PC Patel… - Journal of …, 2023 - academic.oup.com
Objectives We aimed to identify rational empirical dosing strategies for cefepime treatment in
critically ill patients by utilizing population pharmacokinetics and target attainment analysis. …

Commonly used fluoroquinolones cross-react with urine drug screens for opiates, buprenorphine, and amphetamines

JM Colby, PC Patel, DY Fu, NJ Rutherford - Clinical Biochemistry, 2019 - Elsevier
Objectives Fluoroquinolone antibiotics are commonly used in the treatment of infections and
have previously been confirmed to cross-react with previous generations of opiates …

Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis

…, W Fissell, S Rolsma, PC Patel… - Antimicrobial agents …, 2023 - Am Soc Microbiol
In the present study, population pharmacokinetic (PK) analysis was performed based on
meropenem data from a prospective study conducted in 114 critically ill patients with a wide …